One of the most common hormonal conditions affecting women has a new name. In May 2026, a global consensus process published in The Lancet renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). The process drew on input from more than 22,000 clinicians, researchers, and patients over 11 years. Since then, the new name has been endorsed by dozens of professional and patient organizations worldwide, including the Endocrine Society.
Here’s what changed, what didn’t, and what it means if you’re managing this condition or supporting your fertility.
Why the name changed
“Polycystic ovary syndrome” describes the condition by one visible feature — ovarian cysts. But many people with PMOS don’t have visible cysts, and many people with ovarian cysts don’t have the condition at all. The old name also kept clinical attention on the ovaries specifically, even though the condition affects the body’s broader hormonal and metabolic systems. Researchers behind the renaming process point to that mismatch as a driver of delayed diagnoses and treatment plans that managed symptoms without addressing what was driving them.
What PMOS actually stands for
Polyendocrine — Multiple hormone systems are involved, not just reproductive ones. PMOS affects insulin signaling and stress-hormone pathways alongside the systems that regulate ovulation.
Metabolic — Insulin resistance and blood sugar dysregulation are core features of the condition, not side effects of it. Recognizing this as central, rather than incidental, is meant to encourage earlier metabolic screening and more targeted treatment.
Ovarian syndrome — The reproductive picture — irregular cycles, elevated androgens, ovulatory dysfunction — hasn’t gone anywhere. What’s changed is the framing: these are understood as downstream effects of a broader endocrine and metabolic condition, not the root cause of it.
If you've already been diagnosed with PCOS
PMOS and PCOS describe the same condition. Nothing about your medical history or your diagnosis changes because the name did. Medical records, clinical guidelines, and patient materials will transition to PMOS gradually as the new terminology is adopted — that process will take time, and there’s no single date by which every doctor’s office or chart will have caught up.
Your experience with this condition, and the diagnosis you already have, are just as valid as they were before the name changed.
What PMOS means for fertility
Difficulty with ovulation is one of the most common fertility challenges associated with PCOS/PMOS. As research continues to clarify how metabolic health and hormone regulation interact with reproductive function, nutrition has become one part — not the whole — of a comprehensive approach many clinicians recommend alongside medical care.
Certain nutrients have real research behind them here. Myo-inositol and D-chiro-inositol, in particular, have been studied for their role in insulin sensitivity and ovulatory function — which is the research our Balance formula is built around.
Nutrition on its own isn’t a treatment for PMOS. It’s a way to support your broader hormonal health alongside — not instead of — guidance from your doctor.
Supporting hormone health with Balance
Balance was formulated with fertility doctors for women managing the hormonal and metabolic picture associated with PMOS. It delivers a 40:1 ratio of myo-inositol to D-chiro-inositol — the ratio most studied for insulin sensitivity and hormone balance in this condition, and the same ratio naturally found in healthy ovarian follicular fluid.
You may still see “PCOS” on Balance’s product page and elsewhere on our site while we update our language to match the new terminology. The formula hasn’t changed — the science it’s built on just has a more accurate name now.
